Best Life Sciences Companies in Chicago, United States

Provider of wearable neonatal signs monitor. The device is a small low-cost neonatal vital signs monitor integrated into a baby hat and uses a simple sensor array to measure heart rate, respiratory rate, blood oxygen saturation, and temperature. The sensors are powered by rechargeable batteries, and wirelessly transmit data to a central monitor which alerts attending healthcare professionals when a newborn is in immediate danger. It is intended for critically ill newborns being cared for in hospitals in low-resource countries such as Uganda.

Funding rounds

• Apr 2026Conventional Debt$35K
• Nov 2024Conventional Debt$200K
• Sep 2022Conventional Debt$700K
• Apr 2021Seed$1.4M

Founders & team

Teresa CauvelCo-founder and CTO

Investors

Axel Johnson, SUNU Capital, Assiduity Capital, Sorenson Impact Foundation, Villgro Africa, Connetic Ventures

Tech stack

BootstrapGodaddyGoogle CloudGoogle Cloud CdnGoogle WorkspaceGsap

Developer of drugs for the treatment of endocrine disorders. The company is developing targeted therapies that utilize HSD-1 inhibition to address unmet needs in endocrinology and rheumatology such as endogenous Cushing’s syndrome (Cushing’s) and autonomous cortisol secretion (ACS), and autoimmune diseases such as polymyalgia rheumatica (PMR).

Developer of immunotherapeutic solutions for cancer treatment. It offers telomere targeting agent MAIA and THIO for the treatment of multiple cancer by targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity.

Funding rounds

• Dec 2025Post IPO$1.5M
• Sep 2025Post IPO$3M
• Sep 2025Grant (prize money)$770.2K
• May 2025Post IPO$695K

Founders & team

Vlad Vitoc MdFounder and CEO

Investors

Checkmate Capital, BRK Financial Group, HHS, Kizoo

Tech stack

AccessibeApache Http ServerBootstrapCdnjsCloudflareFancybox

Provider of AI based drug discovery platform for drug development. The company licenses or co develops clinical stage therapeutics, optimizing patient selection strategies for accelerated, biomarker driven drug development. It utilizes real world oncology data and patient derived functional genomic data to identify and validate compelling biology, aiming to develop efficacious drugs for patients with unmet needs and enhance patient outcomes.

Funding rounds

• Apr 2025Series D$283M
• Oct 2024Series C$62M

Founders & team

Ryan FukushimaCo-FounderEric LefkofskyCo-FounderIker HuergaCEO

Investors

Revolution, Lightbank, Builders VC, New Enterprise Associates

Tech stack

Apple Icloud MailDudaGoogle WorkspaceHstsJqueryJquery Migrate

Developer of supramolecular therapeutic peptides for regenerative medicine applications. It focuses on creating regenerative therapeutics using supramolecular chemistry to promote healing after traumatic injury and improve human healthspan. The company's platform utilizes supramolecular structures to encode interactions between molecules, activate regenerative signals, and create scaffolds for tissue growth. This technology aims to regenerate cells and tissues effectively without the challenges associated with cell therapies. The company has pipeline programs in neurological and musculoskeletal regeneration.

Funding rounds

• Dec 2025Seed$12.5M
• Sep 2024Grant (prize money)—
• Mar 2022Grant (prize money)$252.9K

Founders & team

Samuel StuppCo-FounderNick Satherex-Co-Founder & Chief Executive OfficerNick SChief Executive Officer

Investors

America’s Seed Fund

Biotech developing novel anti-inflammatory therapies for immune-driven diseases. They focus on identifying and targeting key activators of inflammatory and fibrotic cascades. Their lead monoclonal antibody is designed to address unchecked inflammation in acute and chronic conditions. They employ a platform strategy involving monoclonal antibodies, biomarkers, and genotypes for serious inflammatory, fibrotic, and autoimmune disorders. They are committed to finding novel targets in the treatment of inflammatory diseases and working collaboratively with regulatory bodies to ensure appropriate review for unmet medical needs. They are exploring eNAMPT as a key target and applying the novel biologic therapeutic to address the “unchecked inflammation and fibrosis” elicited by dysregulated innate immunity pathways.

Funding rounds

• Dec 2025Grant (prize money)$2.1M
• May 2025Grant (prize money)$2.5M
• Feb 2025Grant (prize money)$1.9M
• Sep 2022Grant (prize money)$259.6K

Founders & team

Joe Gn Garcia MdFounder and CEO

Investors

NIH, HHS, Ironwood Investment Management, 7Gventurs

Developer of three-dimensional imaging device for skin lesion and cancer tracking. The company develops AnthroCam, a 3D imaging device that creates high-resolution, life-sized avatars of skin surfaces using non-invasive visible light technology. It enables tracking subtle changes for early skin cancer detection, rooted in decades of anatomic imaging research.

Funding rounds

• Mar 2026Seed$1.5M

Founders & team

David TeplicaFounder & CEO & CMO

Developer of lab-on-chip diagnostic technology for cancer and HAI. The company develops CMOS sensor technology systems with existing semiconductor manufacturing technology to address challenges faced by medical professionals and lab researchers. Initial applications being developed include liquid biopsy for cancer, diagnosis of hospital-acquired infections, and environmental monitoring.

Funding rounds

• Sep 2025Grant (prize money)$181.5K
• Apr 2022Grant (prize money)$2M
• Jan 2019Grant (prize money)$300K
• Sep 2018Grant (prize money)$1.7M

Founders & team

Peng Paul LiuPresident and CEO

Investors

HHS, United States Department of Agriculture

Provider of digital depth gauge for the measurement of bones. The company's electronic depth gauge (The EDG) is a digital depth gauge for the orthopedics market. The device is intended to measure surgically created orthopedic bone screw holes. The device makes measurements during surgery, it can be held in one hand, and it consists of a lock to lock the reading of the device. The company also offers a device EDG SPINE which is specific to spine surgeries.

Developing next-generation tools for left-heart access. It offers medical devices and procedures that allow surgeons to access the left side of the heart to treat patients with heart failure and other heart conditions.

Funding rounds

• Apr 2025Series A$29.4M
• Feb 2025Conventional Debt$15M
• May 2024Seed$12.5M
• Feb 2023Seed$5M

Founders & team

Eric SauterCo-Founder

Investors

Mohan Growth Partners, New York Angels

Surgical tools using hyperspectral imaging for safer, more effective procedures. This company develops surgical instruments for the next generation operating room. They are delivering hyperspectral imaging technology integrated into laparoscopic and robotic surgical tools. This platform provides real-time sensing of critical structures to improve safety and outcomes of surgical procedures. They are developing a suite of surgical instruments, including advanced energy, stapler, and dissection solutions. This platform provides dynamic information to surgeons about the presence of hidden structures such as blood vessels, ureters, and nerves, as well as the quality of tissues. The integrated technology offers smart detection in your favorite tools with a smart vision engine for power and precision. It provides real-time visualization of critical structures and fits seamlessly into surgical workflows to provide critical, actionable information displayed onto existing surgical monitors. This is a B2B tech company in the medical device industry.

Funding rounds

• Jul 2025Grant (prize money)$1.4M
• Sep 2024Grant (prize money)$306.7K
• May 2017Grant (prize money)$1.3M
• Dec 2016Grant (prize money)$1.4M

Founders & team

Mayank VijayvergiaLead Engineer and Co-founderJonathan W. Gunn, JD, PhDCTO and Co-founder

Investors

America’s Seed Fund, HHS, GOOSE Capital, TMC Venture Fund

Tech stack

WixReactGoogle CloudHstsGoogle Cloud CdnHttp/3

DeNovX is an innovative pharmaceutical company that provides platform products for pharmaceutical uses. Its pharmaceutical products division is advancing the development of a treatment for ulcerative colitis. The lead product for the same is DNVX-078, for the treatment of mild-to-moderate ulcerative colitis (UC), with platform extension opportunities into other diseases

Funding rounds

• Mar 2025Grant (prize money)$2M
• Sep 2024Grant (prize money)$350K
• Sep 2022Grant (prize money)$2.5M
• Aug 2021Grant (prize money)$313.2K

Founders & team

Andrew BondCo-Founder & COO

Investors

HHS

Tech stack

WordpressMysqlPhpNginxJquery MigrateJquery